Reading this on a mobile device? Try our optimized mobile version here: http://r.smartbrief.com/resp/elmtCfbwocfCtDcdwIeS

February 25, 2013
Sign upForwardArchiveAdvertiseRead more at SmartBrief.com
News for nuclear medicine and molecular imaging professionals
 
The news summaries appearing in SNMMI SmartBrief are based on original information from multiple internet sources and are produced by SmartBrief, Inc., an independent e-mail newsletter publisher. The items below are not selected or reviewed by SNMMI prior to publication. Questions and comments may be directed to SmartBrief at snmmi@smartbrief.com.

  Top Story 
  • Researchers borrow tool from astronomy to detect tumor biomarkers
    Researchers in the U.K. are using image analysis algorithms used by astronomers to identify breast cancer tumor biomarkers. The researchers tested the method on 2,000 breast tumors and discovered that it is as accurate as, but faster than, the standard manual method, according to the study published in the British Journal of Cancer. The researchers plan a bigger study using the method on samples from more than 20,000 patients. Medical News Today (2/22) LinkedInFacebookTwitterEmail this Story
  Clinical News & Research 
  • Peptide may usher nanoparticles past immune system into tumors
    University of Pennsylvania researchers have designed molecules bearing a segment of the membrane protein CD47, which tricks macrophages into allowing drug-bearing nanoparticles into blood cells, according to a study published in Science. The researchers designed a 21-amino-acid peptide based on the CD47 sequence and attached it to polystyrene nanobeads that also included a dye that can be identified using fluorescence spectroscopy. Tests on mice showed the nanobeads sneak past immune cells and accumulate in tumors. Researchers hope the technique can be improved to employ customized nanobeads. Nature (free content) (2/21) LinkedInFacebookTwitterEmail this Story
  Industry Report 
  • Blaze Bioscience raises $8.5M for tumor imaging technology
    Blaze Bioscience has raised $8.5 million that the Seattle-based company plans to use for clinical development of BLZ-100, also called Tumor Paint. The substance illuminates cancer cells, making it easier for surgeons to differentiate diseased tissue from healthy tissue. The cancer cells highlighted by the technology can be visualized with a near-infrared camera. MedCityNews.com (2/22) LinkedInFacebookTwitterEmail this Story
  News from the Field 
  • CMS payment model emphasizes primary care
    Primary care doctors could see a mean 7% increase in Medicare compensation under a new transitional care payment policy from CMS, according to a report in the New England Journal of Medicine. "In adopting the transitional care payment policy, CMS has begun shifting more financial resources toward primary care and opened the door to further increases in primary care payment in return for the greater accountability and efficiency that studies suggest may be attained through a medical-home model," according to the authors. PhysiciansBriefing.com/HealthDay News (2/22) LinkedInFacebookTwitterEmail this Story
  International Developments 
  Health Policy 
  Advancing Health Care 
  From SNMMI 
  • Consumer Reports educates public on amyloid imaging
    Consumer Reports has created a free patient-friendly report, "Testing for Alzheimer's Disease," based on one of SNMMI's recommendations from the Choosing Wisely® campaign. Last week, SNMMI released a list of "Five Things Physicians and Patients Should Question" in nuclear medicine and molecular imaging as part of the campaign. The list identifies targeted, evidence-based recommendations that can support physicians and patients in making wise choices about their care. Read the report. LinkedInFacebookTwitterEmail this Story
  • Maintain your certification with SNMMI's self-assessment modules
    Earn the self-assessment credit hours needed to maintain your certification. New modules are now available, including Bringing Physiology into PET of the Liver, Imaging of Multiple Myeloma and Related Plasma Cell Dyscrasias, Modern Nuclear Imaging for Paragangliomas: Beyond SPECT, Oncologic PET/MRI, Part 1: Tumors of the Brain, Head and Neck, Chest, Abdomen, and Pelvis, and Effectiveness and Safety of FDG-PET in the Evaluation of Dementia. Get started today. LinkedInFacebookTwitterEmail this Story
SNMMI  |  News  |  Meetings  |  Education  |  Publications  |  Membership

SNMMI on Facebook  |  SNMMI on LinkedIn  |  SNMMI on Twitter  |  SNMMI on YouTube

  SmartQuote 
It is wonderful how much news there is when people write every other day; if they wait for a month, there is nothing that seems worth telling."
--Anna Masterton Buchan,
Scottish writer


LinkedInFacebookTwitterEmail this Story

 
 
Subscriber Tools
   
Print friendly format  | Web version  | Search past news  | Archive  | Privacy policy

Advertise
Account Director:   Meryl Harold   (202) 407-7828
 
Read more at SmartBrief.com
 
 
 Recent SNMMI SmartBrief Issues:   Lead Editor:   Melissa Turner
     
Mailing Address:
SmartBrief, Inc.®, 555 11th ST NW, Suite 600, Washington, DC 20004
 
 
© 1999-2013 SmartBrief, Inc.®  Legal Information